When the total number of patients with a KRAS mutation was analyzed regardless of tumor type, the rate of clinical benefit of patients treated with a MEK inhibitor--containing therapy was higher than that of those treated with other therapies (p=0.02). The gene discussed is KRAS; the disease is neoplasm.